Cancer Family
Reproductive System Neoplasm
CI-CAN-00000338Explore in graph →
Non-malignant3,042 active trials38 approved drugs197 evidence items
- NCIt
- C3674
Loading cancer entity…
Cancer Family
CI-CAN-00000338Explore in graph →
Clinical trials
13,672 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07611110 | AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)(VECTRA-01) | recruiting | Phase 3 | 670 | AstraZenecaINDUSTRY | 20 | Aug 26, 2026 | clinicaltrials |
| NCT07788625 | ¹⁸F-PSMA-1007 PET-CT-Directed Focal Therapy for MRI-Invisible Prostate Cancer(FOCUS-PSMA) | recruiting | N/A | 60 | The University of Hong KongOTHER | 1 | Aug 26, 2026 |
| clinicaltrials |
| NCT03067181 | Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors | recruiting | Phase 3 | 1,780 | Children's Oncology GroupNETWORK | 9 | Aug 25, 2026 | clinicaltrials |
| NCT03959085 | Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy | recruiting | Phase 3 | 5,951 | Children's Oncology GroupNETWORK | 5 | Aug 25, 2026 | clinicaltrials |
| NCT04847063 | Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies | recruiting | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04851119 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | recruiting | Phase 1 / Phase 2 | 147 | Children's Oncology GroupNETWORK | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05483491 | KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer | recruiting | Phase 1 | 30 | Christian HinrichsOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06022822 | Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial | recruiting | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06085664 | A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy | recruiting | Phase 1 / Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06276491 | Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors | recruiting | Phase 1 | 282 | Xencor, Inc.INDUSTRY | 4 | Aug 25, 2026 | clinicaltrials |
| NCT07316686 | Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma | recruiting | Phase 1 | 18 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07776821 | An Exploratory Study on the Efficacy and Safety of Enlonstobart Combined With Concurrent Radiotherapy and Chemotherapy Following Induction Therapy With Enlonstobart Plus Chemotherapy in Patients With Locally Advanced Cervical Cancer. | recruiting | Phase 4 | 31 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07779109 | Pelvic Ultra-Hypofractionated Adjuvant Radiotherapy for Endometrial Cancer (PURE-cohort)(PURE-cohort) | recruiting | N/A | 50 | Instituto de Investigación Sanitaria AragónOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06459271 | Feasibility of CALM in Patients With Ovarian Cancer | recruiting | N/A | 50 | University Health Network, TorontoOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07745361 | Study of Oral MRT-2359 With Apalutamide in Prostate Cancer(MODeFIRe-1) | recruiting | Phase 2 | 25 | Monte Rosa Therapeutics, IncINDUSTRY | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07783022 | Real-World Study of Niraparib in First-Line Maintenance Therapy for Advanced Epithelial Ovarian Cancer | recruiting | — | 1,920 | Fudan UniversityOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT04221542 | Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 | 479 | AmgenINDUSTRY | 10 | Aug 21, 2026 | clinicaltrials |
| NCT05548296 | A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma | recruiting | Phase 2 | 350 | Acrivon TherapeuticsINDUSTRY | 5 | Aug 21, 2026 | clinicaltrials |
| NCT05797168 | Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors(FONTANA) | recruiting | Phase 1 / Phase 2 | 602 | AstraZenecaINDUSTRY | 12 | Aug 21, 2026 | clinicaltrials |
| NCT05805371 | PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 | 21 | City of Hope Medical CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06369246 | PRORAD-5 PROstate RADiation in 5 Fractions: Phase II Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer. | recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06468215 | Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer | recruiting | N/A | 16 | Peking University People's HospitalOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06774963 | A Phase 1 Study of LNCB74 in Advanced Solid Tumors(LNCB74-01) | recruiting | Phase 1 | 145 | NextCure, Inc.INDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06844383 | A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide(TALENT) | recruiting | Phase 2 | 126 | Prostate Cancer Clinical Trials ConsortiumOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07454603 | A Single-arm, Multicenter Prospective Study to Evaluate the Diagnostic Performance of PROSTest in Men With PSA ≥ 3ng/ml Using Biopsy as the Sole Ground Truth(PROSTest_STRAT) | recruiting | — | 1,500 | Wren Laboratories LLCINDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07524114 | Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)(SHERLOCK) | recruiting | — | 7,000 | University Health Network, TorontoOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07623369 | A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 299 | Huahui HealthINDUSTRY | 2 | Aug 21, 2026 | clinicaltrials |
| NCT04945642 | High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma(HYDRA) | recruiting | N/A | 52 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05269381 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors(PNeoVCA) | recruiting | Phase 1 / Phase 2 | 138 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05636111 | Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer | recruiting | Phase 1 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06060873 | MAGESTIC Trial: MiRNA in Detecting Active Germ Cell Tumors in Early Suspected and MetastaTIC Disease Trial | recruiting | — | 418 | University of Southern CaliforniaOTHER | 2 | Aug 20, 2026 | clinicaltrials |
| NCT06538337 | Hypofractionated External Beam Radiotherapy With Adaptive Planning for Endometrial and Cervical Cancers(HERA) | recruiting | N/A | 60 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06785636 | A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC(P300) | recruiting | Phase 1 / Phase 2 | 120 | Pathos AI, Inc.INDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06864533 | Adjuvant Chemotherapy for High Malignant Prostate Cancer(PKUFH-GS5) | recruiting | — | 315 | Peking University First HospitalOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06945172 | Comparison of Prostate Cancer-related Quality of Life in Sexually Active Men With Favourable Intermediate-risk Localised Prostate Cancer Treated With Total Prostatectomy or Focal HIFU(QUALIFY) | recruiting | N/A | 102 | GCS Ramsay Santé pour l'Enseignement et la RechercheOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07077239 | Prostate Cancer Postoperative Stereotactic Body Radiotherapy With Adaptive Technology for Minimizing Toxicity(MASAMUNE) | recruiting | — | 200 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07227077 | Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial | recruiting | N/A | 50 | Medical College of WisconsinOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07644598 | MRI-based Focal Intraprostatic Simultaneous Integrated Boost (SIB) Intensification With De-escalated Adaptive-risk SBRT for Patients With Low to Intermediate Risk Prostate Cancer(MIDAS) | recruiting | Phase 2 | 58 | Georgetown UniversityOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07690189 | Study of NTB-928 in R/R OC | recruiting | Phase 1 | 90 | TeneoSeven, Inc.INDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT03604315 | Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF | recruiting | Phase 1 | 300 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04104776 | A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | recruiting | Phase 1 / Phase 2 | 300 | Novartis PharmaceuticalsINDUSTRY | 7 | Aug 19, 2026 | clinicaltrials |
| NCT04423211 | Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging | recruiting | Phase 3 | 804 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04567771 | Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer | recruiting | N/A | 121 | Mayo ClinicOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04775355 | Study to Detect Changes in Urinary and Gut Microbiome During Androgen Deprivation Therapy and Radiation Therapy in Patients With Prostate Cancer | recruiting | — | 30 | City of Hope Medical CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07109427 | Impact of an Electronic Health Record Maintenance Alert on PSA Screening Rates in a 10-Hospital Integrated Health System | recruiting | N/A | 40,000 | Washington University School of MedicineOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07231627 | AI Algorithm-Informed Biopsy for Prostate Cancer Detection With Indeterminate and Low-Risk Prostate MRI Lesions | recruiting | N/A | 50 | University of ArkansasOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07237269 | Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer | recruiting | Phase 2 | 140 | University of NebraskaOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05277688 | Adjuvant Concurrent Chemoradiotherapy Versus Radiotherapy in Early-stage Cervical Cancer Patients | recruiting | Phase 3 | 340 | Ruijin HospitalOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06850402 | Evaluation of a Novel Optical Microscope With a Deep Depth of Field (DeepDOF) to Provide Histologic-quality Images on Cervical Biopsies and Loop Electrosurgical Excision Procedure (LEEP) Specimens at the Point-of-care | recruiting | N/A | 400 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06966024 | Study of DCC-2812 in Participants With Advanced Genitourinary Cancers | recruiting | Phase 1 | 60 | Deciphera Pharmaceuticals, LLCINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 26, 2026source: clinicaltrials